WEKO3
インデックスリンク
アイテム
{"_buckets": {"deposit": "7723fc5f-375c-4cc8-917e-1bf2e58b0613"}, "_deposit": {"created_by": 18, "id": "53610", "owners": [18], "pid": {"revision_id": 0, "type": "depid", "value": "53610"}, "status": "published"}, "_oai": {"id": "oai:kanazawa-u.repo.nii.ac.jp:00053610", "sets": ["2821"]}, "author_link": ["24844", "95244"], "item_9_biblio_info_8": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2013-05-22", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "4p.", "bibliographicVolumeNumber": "2011 – 2012", "bibliographic_titles": [{"bibliographic_title": "平成24(2012)年度 科学研究費補助金 若手研究(B) 研究成果報告書"}, {"bibliographic_title": "2012 Fiscal Year Final Research Report", "bibliographic_titleLang": "en"}]}]}, "item_9_creator_33": {"attribute_name": "著者別表示", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Mori, Noriko"}], "nameIdentifiers": [{"nameIdentifier": "24844", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30579660", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30579660"}, {"nameIdentifier": "30579660", "nameIdentifierScheme": "研究者番号", "nameIdentifierURI": "https://nrid.nii.ac.jp/nrid/1000030579660"}]}]}, "item_9_description_21": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "子宮内膜癌検体の免疫組織染色法で、HER2発現は、p-AKT発現とは相関が認められなかったが、p-mTOR発現と負の相関が認められ、優位な予後不良因子であった。子宮内膜癌細胞株でHER2を抑制すると、p-AKT の発現低下とMPAや抗癌剤への軽度の感受性増強を認めた。抗HER2モノクローナル抗体のTrastuzumabは、低用量PTXの感受性増強に効果が認められ、HER2をターゲットとした分子標的薬の有効性を推測できた。", "subitem_description_type": "Abstract"}, {"subitem_description": "Immunohistochemical analysis using surgical specimens of endometrial cancers showed a negative correlation between HER2 expression and phosphorylated (p)-mTOR but not p-AKT. Kaplan-Meier analysis revealed that high HER-2 expression appeared to be a risk factor of survival rate. Short interfering RNA (siRNA)-based knockdown of HER-2 reduced p-AKT expression and slightly increased sensitivity to MPA and paclitaxel (PTX) in endometrial cancer cells. Trastuzumab, anti-HER2 monoclonal antibody, enhanced sensitivity to low dose of PTX in endometrial cancer cells. This study suggested the efficacy of new HER2 targeted therapy for endometrial cancer.", "subitem_description_type": "Abstract"}]}, "item_9_description_22": {"attribute_name": "内容記述", "attribute_value_mlt": [{"subitem_description": "研究課題/領域番号:23701097, 研究期間(年度):2011-2012", "subitem_description_type": "Other"}, {"subitem_description": "出典:研究課題「HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発」課題番号23701097\n(KAKEN:科学研究費助成事業データベース(国立情報学研究所))\n(https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/)を加工して作成", "subitem_description_type": "Other"}]}, "item_9_description_5": {"attribute_name": "提供者所属", "attribute_value_mlt": [{"subitem_description": "金沢大学医薬保健研究域医学系", "subitem_description_type": "Other"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.24517/00059892", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_relation_28": {"attribute_name": "関連URI", "attribute_value_mlt": [{"subitem_relation_name": [{"subitem_relation_name_text": "https://kaken.nii.ac.jp/search/?qm=30579660"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://kaken.nii.ac.jp/search/?qm=30579660", "subitem_relation_type_select": "URI"}}, {"subitem_relation_name": [{"subitem_relation_name_text": "https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23701097/"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23701097/", "subitem_relation_type_select": "URI"}}, {"subitem_relation_name": [{"subitem_relation_name_text": "https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/"}], "subitem_relation_type_id": {"subitem_relation_type_id_text": "https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/", "subitem_relation_type_select": "URI"}}]}, "item_9_version_type_25": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "森, 紀子"}], "nameIdentifiers": [{"nameIdentifier": "95244", "nameIdentifierScheme": "WEKO"}, {"nameIdentifier": "30579660", "nameIdentifierScheme": "e-Rad", "nameIdentifierURI": "https://kaken.nii.ac.jp/ja/search/?qm=30579660"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-11-20"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "ME-PR-MORI-N-kaken 2013-4p.pdf", "filesize": [{"value": "339.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_11", "mimetype": "application/pdf", "size": 339200.0, "url": {"label": "ME-PR-MORI-N-kaken 2013-4p.pdf", "url": "https://kanazawa-u.repo.nii.ac.jp/record/53610/files/ME-PR-MORI-N-kaken 2013-4p.pdf"}, "version_id": "b56606e2-7c64-4f13-ada1-b2e95326656a"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "子宮内膜癌", "subitem_subject_scheme": "Other"}, {"subitem_subject": "HER2", "subitem_subject_scheme": "Other"}, {"subitem_subject": "分子標的治療薬", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "jpn"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "research report", "resourceuri": "http://purl.org/coar/resource_type/c_18ws"}]}, "item_title": "HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発"}, {"subitem_title": "Development of HER2 targeted therapy for endometrial carcinoma", "subitem_title_language": "en"}]}, "item_type_id": "9", "owner": "18", "path": ["2821"], "permalink_uri": "https://doi.org/10.24517/00059892", "pubdate": {"attribute_name": "公開日", "attribute_value": "2020-11-20"}, "publish_date": "2020-11-20", "publish_status": "0", "recid": "53610", "relation": {}, "relation_version_is_last": true, "title": ["HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発"], "weko_shared_id": -1}
HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発
https://doi.org/10.24517/00059892
https://doi.org/10.24517/00059892cefbf567-04b7-498e-b844-998bf94d6906
名前 / ファイル | ライセンス | アクション |
---|---|---|
ME-PR-MORI-N-kaken 2013-4p.pdf (339.2 kB)
|
Item type | 報告書 / Research Paper(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2020-11-20 | |||||
タイトル | ||||||
タイトル | HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発 | |||||
タイトル | ||||||
言語 | en | |||||
タイトル | Development of HER2 targeted therapy for endometrial carcinoma | |||||
言語 | ||||||
言語 | jpn | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_18ws | |||||
資源タイプ | research report | |||||
ID登録 | ||||||
ID登録 | 10.24517/00059892 | |||||
ID登録タイプ | JaLC | |||||
著者 |
森, 紀子
× 森, 紀子 |
|||||
著者別表示 |
Mori, Noriko
× Mori, Noriko |
|||||
提供者所属 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 金沢大学医薬保健研究域医学系 | |||||
書誌情報 |
平成24(2012)年度 科学研究費補助金 若手研究(B) 研究成果報告書 en : 2012 Fiscal Year Final Research Report 巻 2011 – 2012, p. 4p., 発行日 2013-05-22 |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | 子宮内膜癌検体の免疫組織染色法で、HER2発現は、p-AKT発現とは相関が認められなかったが、p-mTOR発現と負の相関が認められ、優位な予後不良因子であった。子宮内膜癌細胞株でHER2を抑制すると、p-AKT の発現低下とMPAや抗癌剤への軽度の感受性増強を認めた。抗HER2モノクローナル抗体のTrastuzumabは、低用量PTXの感受性増強に効果が認められ、HER2をターゲットとした分子標的薬の有効性を推測できた。 | |||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Immunohistochemical analysis using surgical specimens of endometrial cancers showed a negative correlation between HER2 expression and phosphorylated (p)-mTOR but not p-AKT. Kaplan-Meier analysis revealed that high HER-2 expression appeared to be a risk factor of survival rate. Short interfering RNA (siRNA)-based knockdown of HER-2 reduced p-AKT expression and slightly increased sensitivity to MPA and paclitaxel (PTX) in endometrial cancer cells. Trastuzumab, anti-HER2 monoclonal antibody, enhanced sensitivity to low dose of PTX in endometrial cancer cells. This study suggested the efficacy of new HER2 targeted therapy for endometrial cancer. | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 研究課題/領域番号:23701097, 研究期間(年度):2011-2012 | |||||
内容記述 | ||||||
内容記述タイプ | Other | |||||
内容記述 | 出典:研究課題「HER2をターゲットとした子宮内膜癌の新たな分子標的治療の開発」課題番号23701097 (KAKEN:科学研究費助成事業データベース(国立情報学研究所)) (https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/)を加工して作成 |
|||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://kaken.nii.ac.jp/search/?qm=30579660 | |||||
関連名称 | https://kaken.nii.ac.jp/search/?qm=30579660 | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23701097/ | |||||
関連名称 | https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-23701097/ | |||||
関連URI | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/ | |||||
関連名称 | https://kaken.nii.ac.jp/report/KAKENHI-PROJECT-23701097/23701097seika/ |